MiNK Therapeutics, Inc. (NASDAQ:INKT) Sees Large Increase in Short Interest

MiNK Therapeutics, Inc. (NASDAQ:INKT) was the target of a significant growth in short interest in March. As of March 13th, there was short interest totaling 149,702 shares, a growth of 303.4% from the February 26th total of 37,106 shares. Based on an average daily trading volume, of 1,570,416 shares, the days-to-cover ratio is presently 0.1 days. Currently, 4.1% of the company’s stock are sold short.

Hedge Funds Weigh In On MiNK Therapeutics

An institutional investor recently bought a new position in MiNK Therapeutics stock. DRW Securities LLC acquired a new position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 25,677 shares of the company’s stock, valued at approximately $286,000. DRW Securities LLC owned approximately 0.55% of MiNK Therapeutics at the end of the most recent quarter. 2.87% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised MiNK Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, January 19th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $35.00.

MiNK Therapeutics Stock Performance

MiNK Therapeutics stock opened at $9.63 on Friday. The firm has a market cap of $45.16 million, a PE ratio of -3.18 and a beta of 0.35. The firm’s 50 day moving average price is $11.02 and its two-hundred day moving average price is $12.38. MiNK Therapeutics has a twelve month low of $6.34 and a twelve month high of $76.00.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.